PD-1, chemo, and adaptive radiation for stage 3 lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage 3 non-small cell lung cancer (NSCLC) confirmed by biopsy.
- Your cancer cannot be surgically removed (agreed by a team of doctors).
- Your cancer does not have certain gene changes (like EGFR, ALK, ROS1).
- You have not had any previous treatment for this lung cancer, including radiation to the chest.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests combining chemotherapy, radiation therapy, and two immune-boosting drugs (iparomlimab and tuvonralimab) as a first treatment for locally advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination improves outcomes compared to standard care.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
This trial tests whether adding low-dose radiation and a type of targeted radiation (SBRT) to a combination of immunotherapy (sintilimab) and chemotherapy works better than immunotherapy and chemotherapy alone for people with advanced squamous cell lung cancer.
This trial looks at adding two immunotherapy drugs to radiation and chemotherapy for people with stage 3 lung cancer that cannot be removed by surgery. It compares giving immunotherapy during radiation versus giving it after radiation, to see which way may help control the cancer better.
Hear when a new Sintilimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.